Innerva was established in November of 2021 in Barcelona by same co-founders of dry eye biotech Avizorex Pharma, Patrick Tresserras and Professor Carlos Belmonte, a renowned physiologist in Neuroscience and Key Opinion Leader in Ophthalmology.

Innerva is pursuing a novel therapeutic strategy to treat ocular pain based on the pharmacological blockade of PIEZO2 ion channels in nerve endings of the ocular surface. 

The asset under development was discovered by the University of Tennessee Research Foundation and the US National Institute of Health (NIH), and its IP was licensed to Innerva with global rights.